4 trials newly registered in Immune System Diseases, first posted 2026-11-20 to 2026-11-21, by therapeutic area, largest first. All areas.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis DDY391, Placebo - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 96 | 2027-01-26 | 2026-11-20 |
| An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases. Iptacopan - Complement Mediated Diseases e.g. PNH, IgAN | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2026-11-16 | 2026-11-20 |
| Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes Tirzepatide - Diabetes Type I | Phase 1 | Recruiting | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 12 | 2026-09-27 | 2026-11-20 |
| Real-world Evidence of Inebilizumab in IgG4-RD IgG4-Related Diseases | Not yet recruiting | Peking Union Medical College Hospital | 100 | 2027-01-01 | 2026-11-20 |